Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0360-3016(02)02718-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current Paradigm and Future Directions in the Management of Nodal Disease in Locally Advanced Cervical Cancer.
Cancers (Basel)
January 2025
Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.
Approximately 36% of patients with cervical cancer present with regional nodal metastasis at diagnosis, which is associated with adverse survival outcomes after definitive treatment. In the modern era of chemoradiotherapy (CRT) and image-guided adaptive brachytherapy (IGABT), where excellent local control is achieved for patients with locally advanced cervical cancer (LACC), nodal failure remains a major challenge to cure. To optimize treatment outcomes for node-positive LACC and reduce the incidence of nodal failure, various treatment approaches have been explored, including methods of surgical nodal staging or dissection, RT dose escalation strategies, such as intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) to involved nodes, and elective treatment of subclinical para-aortic (PAO) disease.
View Article and Find Full Text PDFRadiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial.
BMC Cancer
January 2025
Department of Brachytherapy, Saint John's Cancer Center, Lublin, Poland.
Background: The current standard of care (SoC) for patients with extensive-disease small-cell lung cancer (ED-SCLC) is chemo-immunotherapy. The efficacy of radiotherapy (RT) for chest consolidation has been established for patients with ED-SCLC who have responded to chemotherapy. There is a lack of data on incorporating RT as chest consolidation and metastasis-directed therapy for ED-SCLC.
View Article and Find Full Text PDFUltrasound guided Ru106 plaque brachytherapy for treatment of exudative retinal detachment in children with diffuse choroidal haemangioma.
Eye (Lond)
January 2025
Retinoblastoma Service, Royal London Hospital, London, UK.
Purpose: To evaluate the efficacy of ultrasound-guided ruthenium (Ru 106) plaque brachytherapy for treatment of exudative retinal detachment in diffuse choroidal haemangioma (DCH).
Methods: Retrospective analysis of four paediatric patients treated with ultrasound-guided Ru 106 plaque brachytherapy for DCH with total exudative retinal detachment directed to the thickest part of the DCH. A dose of 40 Gy to the tumour apex was delivered in all patients.
Sensitivity of contributing factors to heterogeneity corrections in dosimetry of ocular brachytherapy using iodine-125 COMS plaques.
J Contemp Brachytherapy
October 2024
Department of Radiation Oncology, East Carolina University, Greenville, North Carolina, USA.
Purpose: To investigate sensitivity of contributing factors to heterogeneity corrections in ocular brachytherapy using iodine-125 (I) Collaborative Ocular Melanoma Study (COMS) plaques.
Material And Methods: Using egs_brachy, Monte Carlo (MC) simulations were performed for I COMS plaques (model: IsoAid IAI-125A). Homogeneous dose (D) was estimated under the American Association of Physicists in Medicine Task Group-43 assumptions, with 85 Gy prescribed to a 5 mm depth.
Impact of robust optimization on patient specific error thresholds for high dose rate prostate brachytherapy source tracking.
Brachytherapy
December 2024
Centre for Medical Radiation Physics, University of Wollongong, Wollongong, New South Wales, Australia; St George Cancer Care Centre, Kogarah, New South Wales, Australia; School of Physics, University of Sydney, Camperdown, New South Wales, Australia.
Purpose: The purpose of this study was to compare the effect of catheter shift errors and determine patient specific error thresholds (PSETs) for different high dose rate prostate brachytherapy (HDRPBT) plans generated by different forms of inverse optimization.
Methods: Three plans were generated for 50 HDRPBT patients and PSETs were determined for each of the 3 plans. Plan 1 was the original Oncentra Prostate (v4.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!